NervGen Pharma Corp
XTSX:NGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NervGen Pharma Corp
Free Cash Flow
NervGen Pharma Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NervGen Pharma Corp
XTSX:NGEN
|
Free Cash Flow
-CA$16.8m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Free Cash Flow
$993m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Free Cash Flow
-CA$86.7m
|
CAGR 3-Years
46%
|
CAGR 5-Years
36%
|
CAGR 10-Years
-11%
|
|
|
Cronos Group Inc
TSX:CRON
|
Free Cash Flow
-$190k
|
CAGR 3-Years
87%
|
CAGR 5-Years
75%
|
CAGR 10-Years
22%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Free Cash Flow
-$113.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-117%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Free Cash Flow
CA$35.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
20%
|
|
NervGen Pharma Corp
Glance View
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The firm is advancing its lead compound, NVG-291, which is for the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and Alzheimer’s disease. The firm has two wholly owned subsidiaries are NervGen US Inc. and NervGen Australia Pty Ltd.
See Also
What is NervGen Pharma Corp's Free Cash Flow?
Free Cash Flow
-16.8m
CAD
Based on the financial report for Sep 30, 2025, NervGen Pharma Corp's Free Cash Flow amounts to -16.8m CAD.
What is NervGen Pharma Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-21%
Over the last year, the Free Cash Flow growth was -3%. The average annual Free Cash Flow growth rates for NervGen Pharma Corp have been -2% over the past three years , -21% over the past five years .
